[go: up one dir, main page]

WO2008058234A3 - Pharmaceutical formulations for 1,4-dihyrdropyridine compounds having improved solubility - Google Patents

Pharmaceutical formulations for 1,4-dihyrdropyridine compounds having improved solubility Download PDF

Info

Publication number
WO2008058234A3
WO2008058234A3 PCT/US2007/084068 US2007084068W WO2008058234A3 WO 2008058234 A3 WO2008058234 A3 WO 2008058234A3 US 2007084068 W US2007084068 W US 2007084068W WO 2008058234 A3 WO2008058234 A3 WO 2008058234A3
Authority
WO
WIPO (PCT)
Prior art keywords
dihyrdropyridine
compounds
pharmaceutical formulations
improved solubility
approximately
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/084068
Other languages
French (fr)
Other versions
WO2008058234A2 (en
Inventor
Ashok Tehim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memory Pharmaceuticals Corp
Original Assignee
Memory Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharmaceuticals Corp filed Critical Memory Pharmaceuticals Corp
Publication of WO2008058234A2 publication Critical patent/WO2008058234A2/en
Publication of WO2008058234A3 publication Critical patent/WO2008058234A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

A pharmaceutical composition comprising a 1,4-dihydropyridine pharmaceutical agent, particularly (+)-isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1,4-dihydro-2,6-dimethyl-pyridine-3,5-dicarboxylate), a mixture of glycerol and PEG1500 esters of long fatty acids having a melting point of approximately 44 °C and a hydrophilic/lipophilic balance of approximately 14 (Gelucire 44/14) and d-alpha-tocopheryl polyethylene glycol 1000 succinate (Vitamin E TPGS), and further optionally comprising polyethylene glycol-15-hydroxystearate (Solutol-HS 15) and/or polyoxyl castor oil (Cremophor-EL), exhibits enhanced solubility characteristics.
PCT/US2007/084068 2006-11-08 2007-11-08 Pharmaceutical formulations for 1,4-dihyrdropyridine compounds having improved solubility Ceased WO2008058234A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85750406P 2006-11-08 2006-11-08
US60/857,504 2006-11-08

Publications (2)

Publication Number Publication Date
WO2008058234A2 WO2008058234A2 (en) 2008-05-15
WO2008058234A3 true WO2008058234A3 (en) 2008-06-26

Family

ID=39365371

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/084068 Ceased WO2008058234A2 (en) 2006-11-08 2007-11-08 Pharmaceutical formulations for 1,4-dihyrdropyridine compounds having improved solubility

Country Status (1)

Country Link
WO (1) WO2008058234A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150064232A (en) 2007-05-25 2015-06-10 더 유니버시티 오브 브리티쉬 콜롬비아 Formulations for the oral administration of therapeutic agents and related methods
US8795634B2 (en) 2008-09-12 2014-08-05 Critical Pharmaceuticals Limited Absorption of therapeutic agents across mucosal membranes or the skin
WO2011050457A1 (en) 2009-10-26 2011-05-05 The University Of British Columbia Stabilized formulation for oral administration of therapeutic agents and related methods
WO2014060855A1 (en) * 2012-10-16 2014-04-24 Wockhardt Limited Pharmaceutical compositions of diclofenac or salts thereof
CN106689775A (en) * 2015-11-12 2017-05-24 北京鑫华乐源科技发展有限公司 Production method of feed used for producing eggs rich in xanthophyll and alpha-linolenic acid
WO2019052471A1 (en) * 2017-09-12 2019-03-21 北京福纳康生物技术有限公司 Fullerene composition and preparation method and use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665740A (en) * 1993-12-10 1997-09-09 Bayer Aktiengesellschaft Isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1, 4-dihydro-2,6-dimethyl-pyridine-3,5-dica rboxylate
US6531139B1 (en) * 1997-07-29 2003-03-11 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665740A (en) * 1993-12-10 1997-09-09 Bayer Aktiengesellschaft Isopropyl 2-methoxyethyl 4-(2-chloro-3-cyano-phenyl)-1, 4-dihydro-2,6-dimethyl-pyridine-3,5-dica rboxylate
US6531139B1 (en) * 1997-07-29 2003-03-11 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability

Also Published As

Publication number Publication date
WO2008058234A2 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
WO2008058234A3 (en) Pharmaceutical formulations for 1,4-dihyrdropyridine compounds having improved solubility
MX373796B (en) Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
WO2002067864A3 (en) Coenzyme q products exhibiting high dissolution qualities
EP0999826B1 (en) Self-emulsifying formulation for lipophilic compounds
WO2005063218A3 (en) Pharmaceutical formulations of bisphosphonates
KR102656954B1 (en) Oral taxane compositions and methods
WO2005020962A8 (en) Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
CO4940469A1 (en) ORAL COMPOSITION OF IMPROVED STABILITY INCLUDING A DERIVATIVE OF INDOLINONE AND A MIXTURE OF GLYCERIDES OR POLYETHYLENE GLYCOL ESTERS
JP2007508296A5 (en)
ZA200404584B (en) Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability.
US11116744B2 (en) Pharmaceutical composition for oral administration comprising taxane
US20050232952A1 (en) Self emulsifying drug delivery systems for poorly soluble drugs
EP2058010A4 (en) PHARMACEUTICAL COMPOSITION
WO2008120711A1 (en) Tamibarotene capsule preparation
WO2007100614A3 (en) STABLE NON-CRYSTALLINE FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITOR
IL195892A (en) Use of isatx247, vitamin e tpgs, mct oil, an emulsifier and ethanol in the preparation of a pharmaceutical composition
JP2002080399A (en) Oral drug composition containing verapamil derivative as drug absorbefacient
WO2003000184A3 (en) Truncated apolipoprotein b-containing lipoprotein particles for delivery of components to tissues or cells
JP6484393B2 (en) Pharmaceutical composition containing dutasteride and capsule preparation containing the same
TW200609005A (en) Film-coated tablet with plural coating-layers
KR910016332A (en) Pharmaceutical compositions containing poorly water-soluble drugs
ES2551125T3 (en) Antifungal composition
JP2002516280A5 (en)
WO2019081451A1 (en) Liquid filled formulations of pde5 inhibitors
JP5503939B2 (en) Azelastine hydrochloride-containing capsule

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07864098

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07864098

Country of ref document: EP

Kind code of ref document: A2